Loading...
Topical cidofovir gel applied once daily is more effective than placebo for acyclovir-resistant herpes simplex virus (HSV) disease.
Therapy for acyclovir-resistant HSV infection continues to be unsatisfactory, with intravenous foscarnet the only reliably active treatment. Topical trifluridine is effective against small lesions but must be applied frequently and is difficult to apply evenly to mucocutaneous lesions. Given the toxicity and inconvenience of these agents, other treatment approaches are needed. Cidofovir, which does not require thymidine kinase for activity, is tested in this study as a once-daily topical therapy for this debilitating condition. Patients were eligible for the study if they had at least one external, culture-confi…